{"id":"combination-of-pimecrolimus-and-fluticasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site burning or irritation"},{"rate":null,"effect":"Skin atrophy (with prolonged corticosteroid use)"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pimecrolimus is a calcineurin inhibitor that prevents T-cell proliferation and cytokine release, while fluticasone is a topical corticosteroid that reduces inflammatory responses. Together, they provide dual anti-inflammatory action for localized skin conditions, particularly in pediatric populations where steroid-sparing approaches are beneficial.","oneSentence":"This combination suppresses skin inflammation by blocking T-cell activation (pimecrolimus) and reducing inflammatory mediator production (fluticasone).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:53.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis in pediatric patients"},{"name":"Inflammatory skin conditions in children"}]},"trialDetails":[{"nctId":"NCT00119158","phase":"PHASE4","title":"Combination Therapy for Atopic Dermatitis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2004-10","conditions":"Atopic Dermatitis","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pimecrolimus cream","fluticasone"],"phase":"marketed","status":"active","brandName":"Combination of pimecrolimus and fluticasone","genericName":"Combination of pimecrolimus and fluticasone","companyName":"Children's Hospital of Philadelphia","companyId":"children-s-hospital-of-philadelphia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses skin inflammation by blocking T-cell activation (pimecrolimus) and reducing inflammatory mediator production (fluticasone). Used for Atopic dermatitis in pediatric patients, Inflammatory skin conditions in children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}